cendakimab

targets interleukin-13

Also Known As:

ABT-308; RPC4046

Networked: 4 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cendakimab: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cendakimab: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        cendakimab: 4

Experts

1.	Assouline-Dayan, Yehudith: 2 articles (01/2021 - 01/2019)
2.	Collins, Margaret H: 2 articles (01/2021 - 01/2019)
3.	Dellon, Evan S: 2 articles (01/2021 - 01/2019)
4.	Evans, Larry: 2 articles (01/2021 - 01/2019)
5.	Gupta, Sandeep: 2 articles (01/2021 - 01/2019)
6.	Hirano, Ikuo: 2 articles (01/2021 - 01/2019)
7.	Rothenberg, Marc E: 2 articles (01/2021 - 01/2019)
8.	Safroneeva, Ekaterina: 2 articles (01/2021 - 01/2019)
9.	Straumann, Alex: 2 articles (01/2021 - 01/2019)
10.	Hua, Steven Y: 1 article (01/2021)

Related Diseases

1.	Eosinophilic Esophagitis 01/01/2021 - "Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic Esophagitis." 01/01/2017 - "These results support further investigation of RPC4046 for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). " 01/01/2021 - "The short-term efficacy of RPC4046, a monoclonal antibody against interleukin-13, has been shown in patients with eosinophilic esophagitis (EoE). " 01/01/2019 - "RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis."
2.	Deglutition Disorders (Dysphagia) 01/01/2019 - "The 360-mg RPC4046 group, compared with the placebo group, showed significant reductions in validated endoscopic severity score at all esophageal locations (P < .0001), validated histologic grade and stage scores (both P < .0001), and clinician's global assessment of disease severity (P = .0352); they had a numerical reduction in scores from the dysphagia symptom diary (P = .0733). " 01/01/2023 - "A statistically significant reduction in the mean number of Dysphagia Days experienced was observed with cendakimab 360 mg vs placebo at week 16 (-4.67 vs -1.83; P = 0.0115); an even greater improvement was observed in steroid-refractory patients vs placebo (-4.48 vs -0.04; P = 0.0079). "
3.	Asthma (Bronchial Asthma) 01/01/2017 - "A randomized, double-blind, placebo-controlled, dose-escalation first-in-human study (NCT00986037) was conducted with RPC4046 in healthy adults and patients with mild to moderate controlled asthma. " 01/01/2017 - "These results support further investigation of RPC4046 for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). " 01/01/2017 - "RPC4046 is a novel anti-IL-13 antibody that blocks IL-13 binding to both receptors and more fully blocks the asthma phenotype. " 01/01/2017 - "A unique anti-interleukin (IL)-13 monoclonal antibody, RPC4046, was generated on the basis of differential IL-13 receptor (R) blockade as assessed in a murine asthma model; the safety, tolerability, pharmacokinetics, and pharmacodynamics of RPC4046 were evaluated in a first-in-human study. "
4.	Respiratory Tract Infections (Respiratory Tract Infection) 01/01/2017 - "Non-serious upper respiratory tract infections were more frequent with RPC4046 versus placebo. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Interleukin-13
3.	Steroids
4.	Interleukin-13 Receptors (Interleukin 13 Receptor)
5.	Interleukins